



## **CytoTools AG: DermaTools Biotech GmbH successfully concludes European Phase IIb clinical trials for diabetic foot due to excellent efficacy**

- Preliminary Phase IIb results show outstanding efficacy, confirming previous clinical data from DermaPro® from India and Germany
- Phase III clinical trials planned in Europe can be performed with considerably reduced patient numbers due to the significant results

Darmstadt, June 27, 2012 – CytoTools AG, a technology holding company with investments in the fields of pharmaceuticals and medical products, reports a major success from its subsidiary DermaTools Biotech GmbH. The Phase IIb clinical trials results on the efficacy of DermaPro® in treating diabetic foot indicate outstanding efficacy. These sores, which occur in up to a quarter of patients as a consequence of diabetes, are currently regarded as not treatable with medication. DermaPro® is the world's first and only medication that has shown very significant efficacy accompanied by excellent tolerance in clinical studies. The conclusive statistical evaluation of the European multicentre study is now underway, allowing the precise results of this clinical Phase IIb study to be published shortly. As a consequence, the Phase IIb study can be successfully concluded due to the promising data log and the excellent efficacy that the clinical data that have been gathered to date confirm.

Following an initial independent assessment of the results, the Phase III study that is subsequently planned in Europe can be conducted with a considerably lower number of patients than has been expected to date. Instead of the approximately 400 patients estimated to date, current calculations suggest that the treatment of around 250 patients will suffice. This reduces the duration of the Phase III trials, and also significantly cuts the related costs. As a consequence, there is now no obstacle to the important objective of starting European Phase III trials this year.

Dr. Dirk Kaiser, member of the management board of CytoTools AG and managing director with responsibility for DermaTools Biotech GmbH, expressed his pleasure with the recent results of these studies: "Doctors applying this treatment have confirmed to us on several occasions that they are convinced of the efficacy and medical tolerance of our globally patented therapy DermaPro®. They hope that it will soon receive market approval, allowing this innovative medication to be available to a large number of affected patients." The study's principal investigators will also present the results at an important medical conference about diabetic foot syndrome to be held in September 2012 in India. Together with the licensee for the Indian market, Centaur, as well as Indian opinion-formers and international experts, these groundbreaking clinical results from Europe will be presented to a broad specialist audience in India.

The management of DermaTools is highly satisfied with the initial results of the clinical Phase IIb trials, since the market launch of DermaPro® is drawing closer. The market launch will occur first in India, following the conclusion of the clinical Phase III trials that are currently underway there. For

## **PRESSEINFORMATION**



# CytoTools

this reason, Centaur's management inspected the DermaPro® production facilities in Germany in June, and presented its first volume estimates for the market launch. Centaur was very satisfied with the quality of the production plants, and plans to place its first orders before the end of this year.

The management will push ahead at the same time with discussions with potential pharmaceutical partners that it has already identified, since the European results form the decisive basis for further licensing agreements with international partners.

*This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

**CytoTools AG**, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: approx. 60% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

### **Contact:**

CytoTools AG  
Dr. Mark Andre Freyberg  
Klappacher Str. 126  
64285 Darmstadt  
Tel.: +49-6151-95158-12  
Fax: +49-6151-95158-13  
E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

### **Press contact:**

cometis AG  
Ulrich Wiehle  
Unter den Eichen 7  
65195 Wiesbaden  
Tel.: +49-611-205855-11  
Fax: +49-611-205855-66  
E-Mail: [wiehle@cometis.de](mailto:wiehle@cometis.de)